MarketMoodz
IRTC — iRhythm Holdings, Inc.
Is IRTC overbought or oversold? Here is the current MarketMoodz read.
iRhythm Holdings, Inc. (IRTC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $124.75. The rating moved from Neutral to Oversold on August 18, 2026.
- Public ratingOversold (as of August 19, 2026)
- Last close$124.75
- Last changeMoved from Neutral to Oversold on August 18, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
iRhythm presents a compelling growth profile rooted in a differentiated ambulatory cardiac monitoring platform, recurring diagnostic revenue, and algorithm-driven analytics that support higher-margin services and potential expansion. Near-term outlook benefits from a favorable diagnostics thematic and steady market conditions, while longer-term upside depends on reimbursement stability, successful commercial expansion, and continued clinical differentiation versus wearables and competing monitors. Key risks include payer coverage shifts, regulatory/privacy enforcement in digital health, and execution challenges that could pressure growth or margins.
Key factors
- Category leadership in ambulatory cardiac monitoring with the Zio platform and large installed clinician base driving recurring diagnostic revenues
- Favorable diagnostic & screening thematic tailwinds supporting procedure volumes and demand for reliable, reimbursable cardiac monitoring solutions
- Recurring-revenue model and improving unit economics that can support margin expansion as scale increases and backend analytics mature
- Product and data-driven differentiation (proprietary algorithms and AI-enabled analytics) that can expand indications and upsell opportunities
- Clear growth levers: expanded payer coverage, international rollouts, clinic/hospital partnerships, and potential new diagnostic services
- Recent market environment steady with selective growth interest in diagnostics, reducing near-term volatility from macro headlines
Risks
- Payer reimbursement pressure or strategic rationalization of coverage could materially reduce revenue or slow adoption
- Competition from wearable-device vendors and other cardiac monitoring providers eroding pricing or share
- Regulatory, privacy, or enforcement risk in digital-health segment (e.g., FTC/health-data scrutiny) that could raise compliance costs or restrict data monetization
- Revenue concentration with a limited set of large payers or customers creating sensitivity to contract renewals and pricing negotiations
- Execution risks around scaling international operations, new product launches, and maintaining clinical performance versus alternatives
- Supply-chain constraints or device manufacturing issues that disrupt delivery and clinician trust
- Valuation sensitivity: growth expectations are priced into shares and disappointed guidance could prompt sharp multiple contraction
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for IRTC — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.